WO2009073931A1 - Nutraceutical composition and methods of use - Google Patents

Abstract

A method of modulating inflammation in an organism, which includes administering to an organism a composition including a therapeutic amount of an extract from the plant Biota orientatis. Several key components of the extract of Biota orientalis have been identified that have also been shown to have an effect in dramatically reducing inflammatory responses.

Description

NUTRACEUTICAL COMPOSITIONS AN METHODS OF USE FIELD OF THE INVENTION

The present invention relates generally to nutraceutical compositions and methods of administering them for the treatment of inflammation or inflammation associated disorders.

The present invention also relates to nutraceutical compositions extracts from a plant capable of treating inflammation or inflammation associated disorders.

DESCRIPTION OF THE PRIOR ART

In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date: part of common general Knowledge, or known to be relevant to an attempt to solve any problem with which this specification is concerned.

The use of non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, for the treatment of pain, inflammation and fever is well known. Adverse reactions from such drugs are widespread and increasingly prevalent resulting in over 100,000 hospitalisations in the US in 2001. Some of the newer NSAID's have been shown to increase a patients risk of myocardial infarction by 80%.

Moreover, there have been a number of increased adverse drug reactions (ADR), particularly when the NSAID was taken in combination with a COX-2 inhibitor.

Some common gastrointestinal ADR's observed include, nausea, vomiting, dyspepsia, gastric ulceration and diarrhoea, other more severe ADR's have also been observed to include hypertension, interstitial nephritis, acute renal failure and photosensitivity.

NSAID's work primarily as a COX inhibitor, and certain NSAID's were developed as specific COX-1 or COX-2 inhibitors.

In 2004, the US FDA issued a public health advisory on the safety of Vioxx™, a selective COX-2 inhibitor, on the basis that there was an increase in cardiovascular events observed in those taking the drug. In 2005, the US FDA issued an alert for practitioners in relation to the safety of the NSAID Celebrex™ again on the basis of the observed increase in cardiovascular events in patients taking the drug.

As a result of the above there has been a general reluctance to prescribe known NSAID's in many situations, or to prescribe reduced dosages in an attempt to combat the adverse side effects currently being observed.

NSAID's have long been used in the treatment of joint inflammation as a form of pain relief.

Shark cartilage provides significant improvement in joint health in an experimental model of immune-mediated arthritis (Pivnenko et al., 2005), and may improve sulfate uptake into new proteoglycan molecules.

Similarly, there is clinical evidence for the efficacy of perna mussel as a treatment for degenerative joint disease in dogs (Pollard et al., 2006; Bui and Bierer 2003). Likewise abalone has potential benefits in alleviating and treating joint disease. It has a high concentration of π-3 polyunsaturated fatty acids (Su and Antonas 2004) which are known to reduce the formation of inflammatory eicosanoids (Mesa Garcia et al., 2006) and at least in part account for the inhibition of nitric oxide production (Pearson et al._f 2007).The latter being linked with chondroprotective and analgesic properties (Pearson et al., 2007).

OBJECT OF THE INVENTION

It is an object of the invention to provide a nutraceutical composition for the treatment of inflammation or inflammation associated disorders.

It is an object of the present invention to overcome, or at least substantially ameliorate, the disadvantages and shortcomings of the prior art.

Other objects and advantages of the present invention will become apparent from the following description, taking in connection with the accompanying drawings, wherein, by way of illustration and example, an embodiment of the present invention is disclosed.

SUMMARY OF THE INVENTION In a first aspect of the invention, although this should not be seen as limiting the invention in any way, there is provided a method of modulating inflammation in an organism, the method including administering to an organism a composition including a therapeutic amount of an extract from the plant Biota orientalis.

In a typical method, administering a composition a composition including a therapeutic amount of an extract from the plant Biota orientalis to an organism decreases inflammation in the organism.

In one embodiment, a composition for modulating inflammation including a B. orientalis extract as described herein further includes an additional extract such as mussel extract, abalone extract or powder, shark cartilage powder or combinations thereof.

In one embodiment, the B. orientalis extract can be produced from a simulated digest mimicking gastrointestinal functioning/processing.

In a further aspect of the invention there is a provided a method of inhibiting cox expression in an organism, the method including administering to an organism a therapeutic or prophylactic amount of an extract from the plant Biota orientalis.

In preference, the cox is cox 1. In preference, the cox is cox 2.

In preference, the cox expression is inhibited by greater than 70%"(e.g., 75, 80, 85, 90, 95%)".

A further aspect of the invention resides in the provision of a method of inhibiting IL-1 -Induced INOS expression In an organism, the method including administering to an organism a therapeutic or prophylactic amount of an extract from the plant Biota orientalis.

in yet a further form of the invention, there is a therapeutic composition including a synergistic combination of an extract from the plant Biota orientalis, with one or more of shark cartilage, perna mussel extract or powder and abalone extract or powder. In a further embodiment, the composition comprises an extract_, from the plant Biota orientalis at a concentration of 5-30% by weight, shark cartilage at a concentration of 10-30% by weight, abalone extract at a concentration of 10-30% by weight, and mussel extract at a concentration of 40-60% by weight.

In yet a further form of the invention there is a use of a composition including at least one of the compounds selected from the group consisting of (9Z,13S,15Z)- 12_t13-epoxyoctadeca-9,11,15-trienoic acid, cis, cis, cis-9,12,15-octadecatrieπoic acid (ALA), cis, cis, cis-β,9,12-octadecatrienoic acid (GLA), cis, cis-9,12- octadecadienoic acid and 9-Octadecenoic acid for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of anti-inflammatory conditions.

In preference, the medicament includes an additional extract such as perna mussel extract, abalone extract or powder, shark cartilage powder or combinations thereof.

A further form of the invention resides in a method of treatment for antiinflammatory conditions in a mammal, which includes administering to the mammal a therapeutically effective amount of a polyunsaturated fatty acid.

In preference, the polyunsaturated fatty acid is selected from the group of omega- 3, omega-6, omega-9 and conjugated fatty acids or mixtures thereof.

In preference, the omega-3 fatty acid is selected from the group including: cis,cis,cis-7,10,13-hexadecatrienoic acid; cis,cis,cis-9,12,15-octadecatrienoic acid; cis,cis,cis,cis-6, 9,12,15,-octadecatetrae-noic acid; cis,cis,cis-11,14,17- eicosatrienoic acid; cis.cis.cis.cis-δ.H.^.^-eicosatetraenoic acid; cis,cis,cis,cis,cis-5,8,11 ,14,17-eicosapentaeπoic acid; cis,cis,cis,cis,cis-

7,10,13,16,19-docosapentaenoic acid; cis,cis,cis,cis,cis,cis-4,7_T10,13,16,19- docosahexaenoic acid; cis,cis,cis,cis-9,12,15, 18,21 -tetracosapentaeπoic acid; and cis,cis,cis,cis,cis,cis-6,9, 12, 15,18,21 -tetracosahexaeπoic acid or mixtures thereof.

In preference, the omega-6 fatty acid is selected from the group including: cis.cis- 9,12-octadecadienoic acid; cis,cis,cis-6,9,12-octadecatrienoic acid; cis,cis-11 ,14- etcosadienoic acid; cis,cis,cis-8,11 ,14-eicosatrienoic acid; cis, cis, cis, cis-5, 8,11,14- eicosatetraenoic acid; cis,cis-13,16-docosadienoic acid; cis,cis,cis,cis-7,10,13,16- docosatetraenoic acid; and cis.cis.cis.cis.cis^J.IO.IS.Iβ-docosa-pentaenoic acid or mixtures thereof.

In preference, the omega-9 fatty acid is selected from the group including: cis-9- octadecenoic acid; cis-11-eicosenoic acid; cis,cis,cis-5,8,11-eicosatrienoic acid; cis-13-docosenoic acid; and cis-15-tetracosenoic acid or mixtures thereof.

In preference, the conjugated fatty acid is selected from the group including: 9Z,11E-octadeca-9,11-dienoic acid; 10E,12Z-octadeca-9,11-dieπoic acid; 8E,10E,12Z-octadecatrienoic acid; 8E,10E,12E-octadecatrienoic acid; 8E,10Z,12E-octadecatrienoic acid; ΘE.I IE.ISZ-octadeca-Θ.H .IS-trienoic acid; 9E .11 E₁13E-octadeca-9, 11,13-trieπoic acid ; 9Z, 11 Z, 13E-octadeca-9, 11,13-trienoic acid; 9Z, 11 E.13Z-octadeca-9, 11 ,13-trienoic acid; ΘE.HZ.ISE-octadeca-ΘJ I.Iδ- trienoic acid; ΘE^IZ.ISZ.ISE-octadeca-Θ.H.IS.Iδ-trienoic acid; trans,trans,trans,trans-octadeca-9, 11,13,15-trienoic acid; (9Z₁13S₁15Z)- 12,13- epoxyoctadeca-9,11,15-trienoic acid; and 5Z,8Z,10E,12E,i4Z-eϊcosaπoic acid or mixtures thereof.

In preference, the fatty acid(s) are/is in a form of a salt.

Another form of the invention resides in a pharmaceutical preparation antiinflammatory conditions in a mammal, which includes a therapeutically effective amount of a polyunsaturated fatty acid.

BRIEF DESCRIPTION OF THE DRAWINGS

By way of example, an employment of the invention is described more fully hereinafter with reference to the accompanying drawings, in which:

Figure 1 : Relative expression of cox 1 RNA in IL- 1 stimulated (A) and unstimulated (B) cartilage explants.

Figure 2: Relative expression of cox 2 RNA in IL-1 stimulated (A) and unstimulated (B) cartilage explants.

Figure 3: Relative expression of iNOS RNA in IL-1 stimulated (A) and unstimulated (B) cartilage explants. Figure 4: Relative expression of aggrecaπ RNA in iL-1 stimulated (A) and unstimulated (B) cartilage ^'explants.

Figure 5: Prostaglandin E₂ (PGE₂} production by IL-1 stimulated (A) and unstimulated (B) cartilage explants. ♦ — • represents treatments significantly different from stimulated (A) or unstimulated (B) controls. lndo_sim, SEQ_sim (both doses) and BO₆Im (0.18mg/mL) resulted in significantly lower PGE₂ in stimulated explants compared with stimulated controls. lndo_Sjm and SEQ_sιm lowered PGE₂ production in unstimulated explants relative to unstimulated controls.

Figure 6: Timeline of injections and sample collection; Sample collection consisted of synovial fluid arthrocentesis from left and right intercarpal joints, and jugular venous blood. Dietary supplementation began on day 0 and continued for the duration of the experiment.

Figure 7: Synovial fluid [PGE2] from intercarpal joints of control horses injected with IL-1 (10ng on inj-1 , 100ng on inj-2) or saline in CON (A) and SEQ (B) horses. Healthy horses received a diet containing placebo (CON) or Sasha's EQ (SEQ) for 28 days. Intra-articular IL-1 (10ng in 500μL sterile saline) was injected into the intercarpal joint, and sterile saline (500μL) was injected into the contralateral joint

14 days after commencement of supplementation (inj-1). A second intra-articular injection of IL-1 (100ng in 500μL sterile saline) or saline (500μL) was injected the same joints 24 h later (inj-2). Approximately 1.5mL synovial fluid was aspirated from the intercarpal joints on days pre (before commencement of supplementation), inj-1 and inj-2 (prior to injections), inj-2-2 (8h after 2^nd IL-1 injection), and 1 , 3, 7 and 14 days after 2^nd IL-1 injection. ^* denotes significant change from inj-1 within treatments. Letters denote significant differences between saline and IL-1 within treatments. Changes are significant when p≤0.05.

Figure 8: Synovial fluid [GAG] from intercarpal joints injected with IL-1 (10ng on inj-1, 100ng on inj-2) or saline in CON (A) and SEQ (B) horses. Healthy horses received a diet containing placebo (CON) or Sasha's EQ (SEQ) for 28 days. Intra-' articular IL-1 (10ng in 500μL sterile saline) was injected into the intercarpal joint, and sterile saline (500μL) was injected into the contralateral joint 14 days after commencement of supplementation (iπj-1). A second intra-articular injection of IL- 1 (100ng in 500μL sterile saline) or saline (500μL) was injected the same joints 24 h later (inj-2). Approximately 1.5ml_ synovial fluid was aspirated from the intercarpal joints on days pre (before commencement of supplementation), inj-1 and inj-2 (prior to injections), inj-2-2 (8 h after 2^nd IL-1 injection), and 1, 3, 7 and 14 days after 2^nd IL-1 injection. * denotes significant change from inj-1 within treatments. Letters denote significant difference between IL-1 and saline within treatments. SEQ horses had significantly higher synovial fluid [GAG] than CON horses. Differences were significant when p≤0.05.

Figure 9: Synovial fluid [protein] from intercarpal joints of control horses injected with IL-1 (lOng on inj-1 , 100ng on inj-2) or saline in CON (A) and SEQ (B) horses. Healthy horses received a diet containing placebo (CON) or Sasha's EQ (SEQ) for 28 days. Intra-articular IL-1 (10πg in 500μL sterile saline) was injected into the intercarpal joint, and sterile saline (500μL) was injected into the contralateral joint 14 days after commencement of supplementation (inj-1). A second intra-articular injection of IL-1 (100ng in 500μL sterile saline) or saline (500μL) was injected the same joints 24 h later (inj-2) Approximately 1.5mL synovial fluid was aspirated from the intercarpal joints on days pre (before commencement of supplementation), inj-1 and inj-2 (prior to injections), inj-2-2 (8h after 2^nd IL-1 injection), and 1, 3, 7 and 14 days after 2^nd IL-1 injection. * denotes significant change from inj-1 within treatments. Letters denote significant differences between IL-1 and saline within treatments. Differences were significant when p≤O.05.

Figure 10: Circumference of intercarpal joints injected with IL-1 (10ng on inj-1 , 100ng on inj-2) or saline in CON (A) and SEQ (B) horses. Healthy horses received a diet containing placebo (CON) or Sasha's EQ (SEQ) for 28 days. Intraarticular IL-1 (10ng in 500μL sterile saline) was injected into the intercarpal joint, and sterile saline (500μL) was injected into the contralateral joint 14 days after commencement of supplementation (inj-1). A second intra-articular injection of IL- 1 (100ng in 500μL sterile saline) or saline (500μL) was injected the same joints 24 h later (inj-2). Approximately 1.5mL synovial fluid was aspirated from the intercarpal joints on days pre (before commencement of supplementation), iπj-1 and inj-2 (prior to injections), inj-2-2 (8h after 2^nd IL-1 injection), and 1, 3, 7 and 14 days after 2^nd IL-1 injection. ^* denotes significant change from iπj-1 within treatments. Letters denote significant differences between IL-1 and saline within treatments. Joint circumference of IL-1 -injected joints was significantly lower in SEQ horses than CON horses (p<0 001). Differences were significant when p≤O.05.

Figure 11 : Table 1 showing the primers for aggrecaπ and β-actin.

Figure 12: Table 2 showing the composition of Sasha's EQ powder prepared by combining Abaloπe (AB), New Zealand Green Lipped Mussel (NZGLM), Shark cartilage (SC) and BO (Interpath Pty Ltd, Australia).

Figure 13: Table 3 showing the nutrient composition of Sasha's EQ for feeding to horses-

Figure 14: Chromatographic spectrum of the extract of Biota orientalis oil.

Figure 15: Shows the concentration of NO of each of the isolated fractions in the cell culture assay.

Figure 16: Shows the induced PGE2 level of the isolated fractions Fr1 and Fl. Figure 17: Shows the induced PGE2 level of the isolated fractions FV and Vi

Figure 18: Shows the reduction of IL-1β induced PGF2α levels on fractions Fr1 and Fri.

Figure 19: Shows the reduction of IL-1β induced PGF2α levels on fractions FrV and FrVi.

DETAILED DESCRIPTION OF THE INVENTION

To facilitate an understanding of the invention various terms and abbreviations are used and defined below:

"SEQ" means a blend of New Zealand Green Lipped Mussel, abalone, shark cartilage powder and Biota oil.

"BO" means "Biota oil" being an extract of the seeds of the plant Biota orientalis.

"NZGLM" means New Zealand Green Lipped Mussel,

"sim" means a simulated digest or simulated digestion. "COX" or "cox" means the enzyme cyclooxygenase.

"iNOS" means inducible nitric oxide (NO) synthase.

Biota is an herb native to Western China and North Korea and is known by a number of other names, such as Thuja orientalis, Platycladus stricta, and Platycladus orientalis.

Simulated digests of shark cartilage, NZGLM and abalone have been previously reported to have anti-inflammatory effects in a cartilage expiant model of arthritis by reducing PGE2, GAG and/or nitric oxide (Pearson et al., 2007).

The following data reports alterations in gene expression associated with conditioning cartilage explants with simulated digests of the combination of all four constituents (SEQ; SEQ₆Im), and , to characterize their effects on IL-1-induced PGE₂, GAG, NO₁ cell viability, and genetic expression of cox 1 , cox 2, iNOS and aggrecan.

Methods Expiant cultures

Front legs of market weight pigs (5-7 months old, 200-250lbs) were obtained from a local abattoir. Legs were chilled on crushed ice until dissection. Using aseptic technique, the intercarpal joint was opened and the cartilage surfaces exposed. A 4mm dermal biopsy punch was used to take explants (~0.5mm thickness; 11- 15mg/explant) of healthy cartilage from the weight-bearing region of both articulating surfaces of the intercarpal joint. Cartilage pieces were washed 3 times in DMEM supplemented with NaHCO₃. Two cartilage discs were placed into each well of 24-well tissue culture plates containing DMEM supplemented with amino acids, sodium selenite, manganese sulfate, NaHCO₃ and ascorbic acid (TCM - tissue culture medium). Plates were incubated at 37°C, 7% CO2 in a humidified atmosphere for up to 144h. Every 24 h media was completely aspirated into 1mL microcentrifuge tubes and immediately replaced with control, conditioned and/or stimulated media (described below) before being returned to the incubator. The collected media was stored at -8O⁰C until analysis. Cartilage was harvested at the end of each experiment with one expiant per well stained for cytotoxicity and the remaining cartilage immediately frozen at -8O⁰C. Simulated digestion and ultrafiltration

A simulated digestion procedure was developed to mimic the gastrointestinal processing of ingested dietary supplements. This type of approach has previously been used to improve the bio-assessment of putative nutraceuticals (Rininger et al., 2000; Pearson et al., 2007).

Simulated digests were prepared using SEQ (0.85g), BO (2.5mL (0.85g) ] and indo (0.074g - a positive anti-inflammatory control). Each test substance was individually suspended in 35m L of simulated gastric fluid (37rnM NaCI, 0.03N HCI₁ 3.2mg/mL pepsin), and shaken at 37^βC for 2 h (Rininger et al., 2000). After this, solution acidity was neutralized by adding an equinormal volume of 2.2 N NaOH (1.15mL). To this was added 36.15mL of simulated intestinal fluid (Rininger et al., 2000 - 3OmM K₂HPO₄, 16OmM NaH₂PO₄; 20mg/mL pancreatin; pH adjusted to 7.4) and the resultant mixture shaken in a 37°C incubator for a further 2 h. A "blank" was prepared using identical methodology but without including any test substance. Appropriate volumes of gastric and intestinal fluid were derived from those approximated in a human stomach (Marciani et al., 2005).

Upon completion of the 4-hour incubation, simulated digests of SEQ (SEQ_sim) BO (BO_sιm) and indomethaciπ (indo_8irn) were centrifuged at 3,000 x g for 25 min at 4^βC. The supernatant was decanted and centrifuged a second time at 3,000 x g for 15 min at 4°C. The resulting supernatant was warmed to room temperature and filtered (0.22μm) to remove particulates. This filtrate was further fractioned with an ultrafiltration centrifuge unit with a 5OkDa molecular weight cut-off, (AmiconUltra, Millipore, Mississauga ON), spinning at 3,000 x g for 25 min (room temperature). Filtered simulated digest was stored at 4°C until use for a maximum of 7 days.

Effect of SEQsim and BO_sim on IL-1-induced inflammation

SEQsim was prepared as explained above. Explaπts from 12 pigs were prepared as previously described, and maintained in unconditioned media for the initial 24 h. At 24 hours post-culture. SEQ_SJm, BO_sim (0, 0.06 or 0.18 mg/mL) or indo_sini (0.02mg/mL) was added to TCM (conditioned media). Conditioned media was refreshed every 24 hours for the duration of the experiment. At 72 hours post- culture, and every 24 hours thereafter, explants were stimulated with IL-1 (0 or 10πg/ml_; Medicorp, Montreal, Quebec; Cat #PHC0813). Explants from each animal were exposed to each treatment in duplicate. Explants were cultured for a total of 120 h. Media was analyzed for [PGE₂], [GAG], [NO]. One explant per treatment was collected into sterile phosphate buffered saline (PBS) and immediately stained for cell viability (see below). The second explant was frozen at -80⁰C for RNA extraction (see below).

PGE₂ analysis:

PGE₂ concentration of TCM was determined using a commercially available PGE₂ ELISA kit (The kit has 7% cross-reactivity with PGEi) (Amershaπ, Baie D'Urfe, Quebec). Plates were read using a Victor 3 micraplate reader (Perkin Elmer, Woodbridge ON) with absorbance set at 405πm. PGE₂ standard curves were developed for each plate, and a best-fit 3^rd order polynomial equation with Ff≥Q.QQ was used to calculate PGE₂ concentrations for standards and samples from each plate.

NO analysis:

NO concentration of tissue culture media was determined by the Griess Reaction (Shen et al., 2005). Plates were read using a Victor 3 micraplate reader with absorbance set at 530nm. Sodium nitrite standard curves were developed for each plate, and a best-fit linear' regression equation with Z^≥O.99 was used to calculate NO concentrations, which were compared with the nitrite standard.

Isolation of total RNA and synthesis of cDNA

Total RNA was extracted from cartilage explants using a modified TRlzol procedure (Chan et al., 2005). Frozen cartilage from each animal was pooled according to conditioning and stimulation, and homogenized in Tri-Reagent (100mg tissue/mL; Sigma, Mississauga ON). Chloroform was added to extract RNA followed by vigorous agitation and 2-min incubation at room temperature. Sample was then centrifuged (12,000 x g, 15 min) and RNA was precipitated with an equal volume of 70% ethanol (DEPC). RNA precipitate was applied to an RNeasy mini column (Qiagen, Valencia CA, USA) and RNA was purified according to manufacturer instructions.

For each pooled sample, 1 μg total RNA was converted to single stranded cDNA using Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (Invitrogeπ, Burlington ON) according to manufacturer instructions. Single-strand cDNA was quantified by UV spectrophotometry and diluted with DEPC-H₂O to a final concentration of 10ng/μl_.

Quantitative real time RT-PCR

Primers for porcine iNOS (Granja et al., 2006). Cox1/2 (Bl^'rtek et al., 2006), aggrecan (Fehreπbacher et al., 2003) and β-actin {housekeeping gene; Nishimoto et al., 2005) (Table 1) were prepared (Laboratory Services Division, University of Guelph) and stored at -2O⁰C until use. Cartilage samples from SEQ_sim and BO_sim were evaluated for changes in gene expression, together with cartilage cultured under identical conditions previously with the other 3 components of SEQ (see Pearson et al., 2007 for detailed culture conditions). Twenty five microliter PCR reactions were performed in triplicate using an ABI Prism 7000 sequence detection system (Perkin-Elmer). Amplification of 50ng of each cDNA sample was detected using SYBR-Rox (tnvitrogen, Burlington ON) and compared to a standard curve of pooled cDNA containing equal amounts of cDNA from each sample. A 1.5% agarose electrophoresis gel was used to confirm PCR products. Expression of each gene of interest (G) in each sample was compared to amplification of β-actin (β), and calibrated to unstimulated control explants (ie. fold change for calibrator = 1). Fold change in expression (ΔG / Δβ) is presented in arbitrary units.

Cytotoxicity Staining

Cell viability was determined using a commercially available viability staining kit (Invitrogen; Burlington ON) (Pearson et al., 2007). Briefly, explants were washed in 50OuL PBS and placed into a 96-well microtitre plate (one explant per well), and were incubated in 20OuL of stock stain (4μM C-AM; 8μM EthD-1) for one hour at room temperature. The plate was read from the bottom of each well using 10 horizontal steps, 3 vertical steps, and a 0.1mm displacement. C-AM and EthD-1 fluorescence in live and killed explants were obtained with excitation/emission filters of 485/530nm and 530/685nm, respectively.

Data analysis

Data from analysis of tissue culture media and viability are presented as means ± standard error. Means of replicates from each treatment/animal were analyzed using two-way repeated measures analysis of variance comparing each treatment with unconditioned controls and indomethacin- conditioned controls. Viability data were analyzed using the Student's / test, individually comparing stimulated controls with all other treatments. When a significant F-ratio was obtained, the Holm-Sidak post-hoc test was used to identify significant differences between treatment and/or time. Significance was accepted if p≤0.05.

Due to low cellularity of cartilage explants, it was necessary to pool RNA from explants exposed to the same conditioning and stimulation in order to extract sufficient RNA for a reverse transcription reaction. Thus, PCR data are presented in the text as a mean change in gene expression (calibrated to controls) relative to β-actin ± coefficient of variation for the assay. A calibrated fold expression change ≥ 2 is considered to be biologically relevant (Yang et al., 2002; Schena et al.. 1995) and are discussed in the text as significant differences.

Results PCR

Cox 1 (Figure 1, A and B): IL-1 stimulation of control explants resulted in a 35% increase in cox 1 expression compared with unstimulated controls. Cox 1 expression was decreased by exposure to indo_Sim by 98 and 91.5% in unstimulated and stimulated explants, respectively.

All constituents of SEQ .reduced cox 1 expression in unstimulated explants (range: 76 - 95% inhibition). Importantly, it was observed that BO_Sι_m (0.06mg/ml_) was the most effective cox 1 inhibitor, reducing cox 1 expression by 95% in both unstimulated and stimulated explants.

In addition, it was observed that SEQ_Eim (0.06 and 0.18mg/ml_) reduced cox 1 expression in unstimulated explants by 90 and 80%, respectively. In IL-1 stimulated explants, SEQ_Sim (0.06 and 0.18mg/mL) inhibited cox 1 expression by 57 and 76%, respectively. The least effective cox 1 inhibitor in IL-1-stimulated explants was NZGLM (0.18mg/mL), which increased cox 1 expression by 62%.

Fold change in cox 1 for all samples was > 2 and therefore not considered significant. Cox 2 (Figure 2, A and B): Stimulation of control explants resulted in a significant 4.3-fold increase in cox 2 expression, lndosim reduced expression of cox 2 by 44 and 47% in unstimulated and stimulated explants, respectively. Fold increase in cox 2 for indo_3im-conditioned, I L- 1 -stimulated explants was significant (2.3).

Abalone (0.18mg/mL) significantly increased cox 2 expression in unstimulated explants, showing similar effect on cox 2 (3.7-fold) as IL-I . All other constituents decreased Cox 2 expression in unstimulated explants (range: 56 - 90%).

IL-1 -stimulation resulted in a significant increase in cox 2 expression in those explants conditioned with indOs_m (2.3-fold), SEQs_im (0.06mg/mL; 2.0-fold), NZGLM_81n, (0-18mg/mL; 28.2-fold), and AB_sjm (0.18mg/mL; 41.5-fold). All other constituents prevented a significant increase in IL-1 -induced cox 2 expression; the most effective inhibitor was BO_sim (0.06mg/mL) which inhibited cox 2 expression by 92%. / iNOS (Figure 3, A and B): Stimulation of control explants by IL-1 resulted in a 287- fold increase in iNOS expression. InUo_3J17, conditioning had no effect on iNOS in unstimulated explants. In IL-1 -stimulated explants, indo₈jm conditioning augmented the effect of IL-1 on iNOS expression (725-fold increase).

SEQ and all of its individual constituents significantly increased iNOS expression in unstimulated explants (range: 39 - 2486-fold increase). IL-1 -stimulation resulted in a significant increase in iNOS expression in all conditioned explants. However, compared with IL-1 -stimulated controls, iNOS was significantly inhibited by both doses of SEQβim in a dose-dependent manner (60 and 89% inhibition for 0 06 and O.i8mg/mL, respectively). BO_sim (0.06mg/mL) and AB_sj_m (0.18mg/mL) also significantly inhibited lL-1-induced iNOS expression by 55 and 12%, respectively.

Aggrecan (Figure 4, A and B): Stimulation of control explants with IL-1 resulted in a slight, non-significant decline in aggrecan expression. Conditioning of unstimulated explants with indo_Sjm resulted in 58-fold increase in aggrecan. This increase was completely abolished by stimulation of indosim-conditioned explants with IL-1.

SEQ and all of its constituents significantly increase aggrecan expression in unstimulated explants. SEQ_sιm increased aggrecan expression in unstimulated explaπts in a dose-dependent manner (42.8 and 215.7-fold increase for 0.06 and 0.18mg/mL, respectively).

Stimulation of conditioned explants with. IL-1 resulted in significant increase in aggrecan expression in SEQ and all of its constituents, with the exception of SC_Sι_m (0.18mg/mL; 1.4-fold increase).

Tissue culture experiments:

PGE₂ (Figure 5, A and B): Stimulation of control explants with IL-1 (10ng/ml_) resulted in a significant increase in media [PGE₂] over the 48h stimulation period, resulting in a significant difference between stimulated and unstimulated controls (p=0 03). lndo_slπi (0.02mg/mL) significantly reduced media [PGE₂] in IL-1 stimulated and unstimulated explants compared with stimulated and ustimulated controls, respectively. There was no IL-1-induced increase in media [PGE₂] in explants conditioned with indOsim.

Stimulation with IL-1 of explants conditioned with SEQ_s,_m (0.06 and 0.18mg/mL) did not increase media [PGE₂]. Media [PGE₂] was significantly lower in these explants compared with stimulated and unstimulated control explants (Figure 5, A). In unstimulated explants media [PGE₂] was significantly lower in explants conditioned with SEQ_Sι_m (0.06 and 0.18mg/mL) than in unstimulated controls (Figure 5, B). There was no significant difference in media [PGE₂] between SEQ₃N (0.06 and 0.18mg/mL) and indo_sιm in both IL-1-stimulated and unstimulated explants.

There was no increase in media IPGE₂] subsequent to IL-1 exposure in explants conditioned with BOsi_m (0.06 and 0.18mg/mL) (Figure 5, A). Conditioning of JL-I- stimulated explaπts with BO_siπ1 (0.18mg/mL) resulted in a significantly lower media [PGE₂] than stimulated controls. There was no significant effect of BO_sim on unstimulated explaπts (Figure 5, B).

NO: There was no significant change in media [NO] in unstimulated control explaπts. Exposure of control explants to IL-1 (10ng/mL) resulted in a significant elevation of media [NO] at 24 (1.21 ± 0.1 μg/mL) and 48 h (1.06 ± 0.1 μg/mL). There was no significant effect of indo₆im on [NO] in stimulated or unstimulated explants (Figure 7). Discussion

These experiments assist in describing effects of the simulated digest of SEQ on cox 1 , cox 2, iNOS, and aggrecan gene expression. The gene expression data can then be used to make predictions about the mechanism of action of SEQ.

Alterations in gene expression observed in 1L-1 -stimulated control explants showed a pattern consistent with an inflammatory response. IL-1 stimulation resulted In a small, non-significant increase in cox 1 expression coupled with a significant increase in cox 2 expression, as has been reported by other authors (Kydd et al., 2007).

As shown, indOsi_m showed a cox 1:cox 2 inhibition profile of about 2:1 , which is consistent with rts classification as a cox 1/2 inhibitor (Gerstenfeld et al., 2003). We have also shown that indo_sim does not inhibit IL-1 -induced iNOS expression, consistent with reports by other authors (Palmer et al., 1993). Nor did it influence IL-1 -mediated aggrecan expression in IL-1 -stimulated explants, an effect that has been reported in mechanically stressed cartilage explants (limoto et al., 2005).

These data characterize indomethaciπ as an effective anti-inflammatory predominately through cox inhibition. Its inability to reduce IL-1 -mediated aggrecan expression and its augmenting effect on IL-1 -mediated iNOS expression, however, suggest that cartilage exposed to indomethacin would continue to degenerate through decline in matrix formation and would suffer from increased nitric oxide-mediated cell death. Indeed these adverse effects have been reported in arthritic dogs using prophylactic indomethacin (Hungin and Kean 2001), and indomethacin is associated with worsening of some pathophysiological indicators of arthritis in humans (Rashad et al., 1989; Huakinsson et al., 1995). When indo_βj_m was applied to cartilage explants in the current study, there was an increase in IL- 1 -mediated NO production, but this was not coupled with a decrease in cell viability.

The relative inhibitory profile of SEQ_Si_m on cox 1:cox 2 expression was approximately 1:1 at both doses. In the experiments described herein, SEQ_3im at the lower dose was comparable to indo_3im as a cox 2 inhibitor, whereas the higher dose was a more effective inhibitor of cox 2 than iπdo_Sim- It is therefore predicted that SEQ_$b11 should effectively inhibit PGE₂ production by IL-1 -stimulated explants. This inhibition was observed in the tissue culture exptant experiment. Inhibition of IL-1-mediated PGE₂ production by SEQ_Sιm-conditioned cartilage explants was significant at both doses, and was not statistically different from PGE₂ inhibition by indogi_m. This provides an explanation for the observed clinical benefit of SEQ in relieving pain in arthritic patients (Rukwied et al , 2007; Zhao et al., 2007).

Earlier publications have reported that SC_siπ, and NZGLMsim inhibit PGE₂ production by I L- 1 -stimulated cartilage explants (Pearson et al., 2007). and the data in this application shows that BO$i_m also has this effect. However, it is of interest that, with the exception of SC_£ιm (0.18mg/mL), cox 2 inhibition by the most effective dose of SEQ_s,_m is stronger than any single constituents alone. This points to a synergistic relationship between the constituents.

Given the effective PGE₂-inhibiting, and related cox-inhibiting properties of SEQ_SITT), the effects of SEQ_sim on iNOS were investigated. With a standard 'NSAID-like' mechanism it is predicted that SEQ would also augment iNOS expression in IL-1- stimulated explants. In fact, the opposite was true, and SEQ_91n, was found to significantly and strongly inhibit iNOS expression.

The effect of IL-1 on cellular expression of iNOS and cox 2 is differentially regulated through activation of at least 2 Mitogen Activated Protein Kinases (MAPKs) (LaPointe and Isenovi 1999). Net expression of iNOS and cox 2 are at least partially dependent on the relative amounts of pericellular NO and PGE₂ (Shin et al., 2007). Thus, products which increase pericellular NO can effectively downregulate expression of cox 2, and vice versa (Shin et al., 2007; Kim et al., 2005). This provides some explanation as to why SEQ_sirn showed a significant inhibitory effect on iNOS while many of the individual constituents, including shark cartilage, Biota and NZGLMsim (0.18mg/mL), actually upregulated expression of iNOS.

Conclusions

SEQ is capable of effectively downregulating RNA for iNOS and cox 2. Its effect on iNOS and cox 2 appears to be due to synergy between its four constituents, but it may be related to post-translational inhibition of NO production (Pearson et al., 2007). Models of cartilage inflammation in horses are widely reported, and include intraarticular challenges such as lipopolysaccharide (Jacobsen et al.. 2006), Freunds Complete Adjuvant (Toutain and Cester 2004) or Na-monoiodoacetate (Welch et al., 1991); or surgical disruptions including creation of osteochondral fragments (Frisbie et al., 2007), focal contusion impact injuries (Bolam et al., 2006) and ligamentous transection (Simmons et al., 1Θ9Θ). While these models capably demonstrate maximal activation of a complexity of inflammatory mechanisms within cartilage and associated subchondral bone and soft tissues, they represent a predominately traumatic inflammatory response. They are less representative of the more subtle biochemical, functional and pathophysiological changes in incipient or sub-acute articular inflammation that characterize most cases of lameness in racing horses (Steel et al., 2006).

While non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids remain important therapeutic resources for treatment of overt clinical lameness, nutraceuticals are becoming widespread as a therapeutic and prophylactic management strategy, for horses with low-grade, sub-acute articular damage and for those at risk of developing articular problems (Trumble 2005; Neil et al., 2005). Most research reported on the efficacy and/or safety of these products in arthritis uses in vή^' ro models (Pearson et al., 2007; Chan et al., 2006), or traumatic injury or clinical in vivo research in non-equine species (McCarthy et al., 2006; Cho et al., 2003). Though useful as screening tools, in vitro models cannot account for the systemic effects of a dietary product which may influence outcomes in the articular space

The objectives of this section are to a) produce and characterize a reversible, subclinical model of IL-1 -induced intra-articular inflammation in the horse with respect to PGE₂ and NO production, and GAG release from cartilage; and b) to apply this model to the evaluation of SEQ in mammals, particularly in horses.

Method

Diets: SEQ powder was prepared by combining Abalone (AB), New Zealand Green Lipped Mussel (NZGLM), Shark cartilage (SC) and Biota oil (Interpath Pty Ltd, Australia) according to the composition provided in Table 2. SEQ mixed ration was prepared by combining SEQ powder (10g/kg), molasses (20g/kg) and flavoring (Essential Sweet Horse Essence D 2344. Essentials Inc. Abbotsford, BC.) (1 g/kg) to a sweet feed horse ration (Table 2), and blending in a diet mixer in 5kg batches until fully mixed. Control ration (CON) was prepared using the same sweet feed diet blended with molasses (~20g/kg) and flavoring (1g/kg).

Horses: 11 healthy horses without signs of articular inflammation (3 thoroughbred, 8 standard bred; age 5 - 12 years; 10 geldings, 1 mare) were randomly allocated to either Group A (SEQ; 1.5kg/day; n=6) or Group B (CON; 1.5kg/day; n=5). The 28- day experiment consisted of two phases - Phase 1: pretreatment (14 days); Phase 2: treatment (14 days). Supplementation began on Day 0 and continued for the duration of the experiment (Figure 6). Sample collection occurred on days 0 (pre), 14 (inj-1), 15 (2 samples: inj-2 - taken Immediately before injection; inj-2-2 - taken 8h post-injection), 16 (day 1), 18 (day 3), 21 (day 7) and 28 (day 14); on these days blood was collected from the jugular vein, and synovial fluid was sampled from both intercarpal joints by aseptic arthrocentesis (see below). An inflammatory challenge - recombinant interieukin-1β (IL-1) - was injected into the left or right intercarpal joint on day 14 (ιnj-1 ; 10ng in 500μL sterile saline) and 15 (inj-2; 100ng in 500μL sterile saline). An equal volume of sterile saline was injected into the contralateral intercarpal joint. Joint circumference as an indicator of joint effusion was measured with a tape measure at each sampling of joint fluid.

All horses were turned out in paddocks during the day and housed in box-stalls overnight. They were bedded on wood shavings and offered hay, water, and mineral salts ad libitum. All procedures were approved by the University of Guelph Animal Care Committee in accordance with guidelines of the Canadian Council on Animal Care.

Arthrocentesis: The knees of both the left and right legs were shaved, and the area aseptically prepared using chlorhexadine (4%), and rinsed with 70% isopropyl alcohol. A sterile 22 gauge, 1.5" needle was inserted into the lateral aspect of the left intercarpal joint. A 3 cc sterile syringe was then attached, and approximately 1.5 - 2 ml_ of synovial fluid was aspired and immediately injected into a sterile K2- hepariπ vacutainer. The procedure was then repeated for the right intercarpal joint. On days 14 (inj-1) and 15 (inj-2), IL-1 (500μL) was injected into either the right or left intercarpal (500μL saline injected into contralateral joint) after aspiration of synovial fluid and before removal of the needle hub. Approximately 1.5mL of synovial fluid was removed from the vacutainer and placed into a microcentrifuge tube and spun at 11 ,000 x g for 10 minutes to remove cellular debris. Supernatant was placed into another microcentrifuge tube containing 10μg indomethacin, and frozen at -80⁰C until analyzed for PGE2, GAG and NO. lndomethacin was added to synovial fluid after it was collected in order to prevent further formation of PGE2 during storage of samples The remaining -0.5mL synovial fluid was sent to the Animal Health Laboratory (Univers^'rty of Guelph) for cytological analysis.

Synovial fluid cytology

1.0 - 1.5mL of fluid was removed from the vacutaiπer for PGE₂, NO and GAG analysis (see below), and approximately 0.5m L was analyzed. for total nucleated cell count (Coulter Z2 counter, Beckman Coulter Canada Inc. Mississauga ON), protein (refractometer) and cell differential (on 100 nucleated cells) at the Animal Health Laboratory.

Synovial fluid [PGE₂]:

Synovial fluid^* was thawed to room temperature then incubated with 20μL hyaluronidase (10mg/mL) on a tube rocker for 30 minutes at 37°C to digest hyaluronic acid. Sample was then diluted 1 :2 with formic acid (0.1%), and centrifuged 12,000 x g for 10 minutes. The supernatant was decanted and analyzed for PGE2 by a commercially available ELISA kit (GE Amersham, Baie D'Urfe, Quebec). PGE2 was extracted from the sample using provided lysis reagents to dissociate PGEz from soluble membrane receptors and binding proteins, and then quantified according to kit protocol. Plates were read using a Victor 3 microplate reader (Perkin Elmer, Woodbridge ON) with absorbance set at 450nm. A best-fit 3^rd order polynomial standard curve was developed for each plate (f^≥O.ΘΘ), and these equations were used to calculate PGE₂ concentrations for samples from each plate.

Synovial fluid [GAG]:

Hyaluronic acid in synovial fluid samples were digested with hyaluronidase as described above. GAG concentration of synovial fluid was determined using a 1 ,9- DMB spectrophotometry assay as described by Chandrasekhar et al. (1987). Samples were diluted 1:3 with dilution buffer and placed into a 96- well microti tre plate. Guanidiπe hydrochloride (275g/L) was added to each well followed immediately by addition of 150μL DMB reagent. Plates were incubated in the dark for 10 minutes, and absorbance was read on a Victor 3 microplate reader at 530nm. Sample absorbance was compared to that of a bovine chondroitin sulfate standard (Sigma, Oakville ON). A best-fit linear standard curves was developed for each plate (f^≥O.99), and these equations were used to calculate GAG concentrations for samples on each plate.

Synovial fluid [NO]:

Nitrite (NO_2-), a stable oxidation product of NO, was analyzed by the Griess reaction (Fenton et al., 2002). Undiluted TCM samples were added to 96 well plates. Sulfanilamide (0.01 g/mL) and N-(1)-Napthylethylene diamine hydrochloride (1mg/mL) dissolved in phosphoric acid (0.085g/L) was added to all wells, and absorbance was read within 5 minutes on a Victor 3 microplate reader at 530 nm. Sample absorbance was compared to a sodium nitrite standard.

Data analysis and presentation

Two-way repeated measures (RM) analysis of variance (ANOVA) was used to detect differences between treatments. When a significant F-ratio was obtained, the Holm Sidak post-hoc test was used to identify differences between treatments. One-way RM ANOVA was used to detect differences within treatments with respect to time. For blood and synovial fluid data, one-way comparisons of data _αwere made against pre- and inj-1 data, as each represented baseline for diet and IL-1 injections, respectively. Data are presented as means ± SEM. Graphs for biochemistry and hematology data are scaled to physiological reference intervals unless otherwise stated. Reference intervals are those published by the Animal Health Laboratory, University of Guelph

(http://www.labservices.uoguelph.ca/units/ahl/files/AHL-userguide.pdf).

Results

Synovial fluid

PGE₂: CON horses: There was no significant change in synovial fluid [PGEz] in saline- injected joints at any time (Figure 7, A). Relative to pre-injection concentrations, [PGE₂] was significantly increased at inj-2-2 (321.3 ± 161.8 pg/mL; p=0.04) in IL-1- injected joints, at which time synovial fluid [PGE₃] was significantly higher in IL-1- iπjected joints than in saline-injected joints (p<O.OO1).

SEQ horses: Data represent π=5, as one outlier horse was removed from the analysis. PGE2 did not change in saline-injected joints of SEQ horses. Like CON horses, there was a spike in [PGE₂] increased at inj-2-2 (175.4 ± 89.2 pg/mL) in IL- 1 -injected joints of SEQ horses (Figure 7, B). However, this increase was not significant when compared with pre-iπjection concentrations. PGE₂ response to saline injection was not different in SEQ horses compared with CON horses. There was no significant difference in PGE₂ response to IL-1 injection compared with saline in SEQ horses.

Although mean [PGE₂] at inj-2-2 in SEQ horses was approximately 55% that of CON horses, variability about the means resulted in no significant difference between diets.

GAG:

CON horses: Synovial fluid [GAG] increased in saline-injected joints between inj-1 (18.3 ± 6.8 μg/mL) and day 1 (48.1 ± 9.6 μg/mL) (Figure 8, A). Injection of IL-1 (10ng) caused a rapid and significant increase in synovial fluid [GAG] between iπj- 1 (24.5 ± 7.3 μg/mL) and inj-2 (77.6 ± 4.4 μg/mL). Synovial fluid [GAG] remained significantly elevated in IL-1 -injected joints at inj-2-2 (66.0 ± 9.6 μg/mL) and day 1 (53.3 ± 11.4.μg/mL) compared with pre-injection concentrations. The magnitude of increase in synovial fluid [GAG] was significantly higher in IL-1-injected joints than in saline-injected joints (p=0.003).

SEQ horses: Synovial fluid [GAG] tended to increase (p=0.09) in both saline- and IL-1 -injected joints between pre (saline: 29.3 + 5.9 μg/mL; IL-1: 27.0 ± 10.8 μg/mL) and inj-1 (saline: 85.5 ± 28.0 μg/mL; IL-1; 83.2 ± 27.9 μg/mL), suggesting an effect of diet on synovial fluid [GAG] (Figure 8, B). There was no change in synovial fluid [GAG] in saline- or IL-1 -injected joints over the course of the experiment. There was no significant difference in synovial fluid [GAG] of IL-1 -injected and saline- injected joints. Synovial fluid [GAG] in IL-1- and saline-injected joints was significantly higher in SEQ horses than CON horses (p<0.001). This difference, was mainly an effect of diet, and not an effect of IL-1 , as evidenced by the fact that the majority of the increase occurred prior to any IL-1 injection.

NO:

CON horses: Synovial fluid [NO] was low and variable over the course of the experiment in both saline- and IL-1 -injected joints. There was no significant effect of either saline or IL-1 injection on NO levels in CON horses over time (data not Shown). The magnitude of synovial fluid [NO] was not different between IL-1- and saline-injected joints.

SEQ horses: There was no change in synovial fluid [NO] in IL-1- or saline-injected joints at any time over the course of the experiment. There was no significant difference between IL-1 or saline at any time.

There was no significant effect of diet on synovial fluid [NO] in IL-1- or saline- injected joints.

Synovial fluid cytology:

CON horses: Pre-injection total cell count (0.61 ± 0.1 x 1 O⁹/L) was significantly elevated by provision of exogenous IL-1 (10 ng) at inj-2 (40.17 + 16.1 x 10^θ/L). Cell count was not further increased following the 2^nd IL-1 injection (100 ng). but remained slightly (but not significantly) elevated through day 1. lnj-1 cell count in saline-injected joints (0.6 + 0.2 x 10⁹/L) increased mildly, reaching a maximum at day 1 (6 0 ± 2.6 x 10⁹/L), but this increase was not significant. Total cell counts of saline- and IL-1 injected joints were significantly different from each other at inj-2 [ie. 24 h after the 1^S| IL-1 injection (10 ng)]. The increase in cell count was due mainly to an increase in the relative percentage of neutrophils. Percent neutrophils significantly Increased in both IL-1- and saline-injected joints after the first injection. Neutrophil counts significantly declined in both IL-1- and saline-injected joints between day 1 and 3 without further increase for the remainder of the experiment There was no difference in % neutrophils between IL-1- and saline-injected joints (data not shown). SEQ horses: Pre-injection total cell count (0.4 ± 0 03 x 10⁹/L) was significantly elevated by provision of exogenous IL-I (10 ng) by inj-2 (27.5 ± 8.7 x 10⁹/L). Cell count was not further increased by inj-2-2, but remained significantly elevated through day 1. lnj-1 total cell count in saline-injected joints (0.4 ± 0.1 x 10^δΛ_) increased mildly, reaching a maximum at inj-2-2 (4.0 ± 2.6 x 10⁹/L), but this increase was not significant. Total cell counts of saline- and IL-I injected joints were significantly different from each other at inj-2 (ie. 24 h after the 1^$l IL-1 injection of 10 ng), inj-2-2 (ie. 8 h after the 2^nd IL-1 injection of 100ng), and day 1 (ie. 24 h after the 2"* IL-1 injection of 100ng). Percent neutrophils significantly increased in both IL-1- and saline-injected joints after the first injection. Increase in neutrophil concentration of saline-injected joints may have been attributable to minor inflammation being caused by injection trauma. Neutrophil counts (%) significantly declined in both IL-1- and saline-injected joints between day 1 and 3 with a second significant spike on day 7. There was no difference in % neutrophils between IL-1- and saline-injected joints.

There was no significant difference in the effect of SEQ and CON diets on total cells counts or % neutrophils in IL-1- or saline-injected joints.

CON horses: Synovial fluid [protein] was significantly increased by injection of 10 ng IL-1 (20 ± 0.0 g/L to 39.4 ± 4.0 g/L) (Figure 9, A). [Protein] was not further increased by injection of 100ng IL-1, and significantly declined 24 h after the 100ng injection. Injection of saline also resulted in a significant increase in [protein] immediately after the first injection, returning to baseline concentrations by day 1 (25.5 ± 1.5 g/L). The magnitude of increase in [protein] over the course of the experiment was significantly higher in IL-1 -injected than saline-injected joints (p=0.01).

SEQ horses: Injection of 10 ng IL-1 resulted in a significant increase in synovial fluid protein on inj-2 (38.7 ± 4.9 g/L), inj-2-2 (36.2 ± 4.4 g/L), and day 1 (27.8 ± 3.8 g/L) compared with inj-1 (20 ± 0 g/L) (Figure 9, B). There was no further effect of the 2^nd IL-1 injection of 100 ng on [protein]. Saline injection also resulted in a Significant increase in [protein] on inj-2-am (27.5 ± 3.0 g/L) and inj-2-pm (25.8 + 2.5 g/L) compared with inj-1 (20.6 ± 0.6 g/L). The magnitude of increase in synovial fluid [protein] was significantly higher in IL-1 -injected joints than in saline-injected joints (p=0.003). There was no significant difference in the effect of SEQ and CON diets on synovia fluid [protein] in IL-1- or saline injected joints.

Joint circumference:

CON horses: There was no significant change in circumference over time in IL-1- or saline-injected joints, and there was no significant difference in joint circumference between IL-1- and saline-injected joints (Figure 10, A).

SEQ horses: There was a significant increase in joint circumference in IL-1- injected joints between rnj-1 (31.1 ± 0.2 cm) and iπj-2 (31.9 ± 0.5 cm) in SEQ horses (Figure 10, B). Joint circumference remained significantly elevated at inj-2- 2 (31.7 ± 0.4 cm) before declining to pre-injection levels. Exactly the same pattern was shown in the saline-injected joints of SEQ horses.

Joint circumference of IL-1 -injected joints was significantly lower in SEQ horses than CON horses (p<O.OO1)

Discussion

This data shows a minimally invasive, reversible model of early stage articular inflammation that can be used to evaluate putative anti-inflammatory nutraceuticals.

The double IL-1 injection protocol resulted in a statistically significant increase in PGE2 at 8h after the 2^nd injection. None of the CON horses were overtly lame at the walk or brief trot at any time during the experiment, despite mean peak synovial fluid [PGE₂] (498 pg/mL) being commensurate with that associated with lameness in horses (488 pg/mL; de Grauw et al., 2006). The increase in PGE₂ was not accompanied by a concomitant increase in NO. This provides a possible explanation as to why these horses were not lame, as transmission and perception of nociceptive pain occurs predominately as a result of combined effect of elevated PGE2 and NO. CON horses may have demonstrated a low-grade lameness had they been subjected to moderate exercise, but this was not undertaken due to the confounding effect of exercise on synovial fluid [PGE₂] (van den Boom et al., 2005). The observed increase in synovial fluid [PGE₂] in CON horses provides good evidence for a low-grade IL-1 -induced inflammation within the joint. We hypothesized that this increase would be blunted by dietary provision of an efficacious anti-inflammatory nutraceutical.

Trafficking of inflammatory cells and release of glycosaminoglycan into the synovial fluid were more sensitive to stimulation wfth IL-1 than production of PGE₂, as an increase in synovial fluid [GAG] and [neutrophils] was observed 24 h after the initial 10 πg IL-1 injection. Synovial fluid [protein] was .also elevated immediately after the 1^SI IL-1 injection. These parameters were not further increased by provision of a higher IL-1 challenge. These responses are consistent with a 'pre-arthritic' inflammatory state (Adarichev et al., 2006). Genes turned on in the early stage of arthritis are predominately those associated with transcription of chemokϊnes, cytokines (notably, IL-1), and metalloproteinases, notably, MMP-13 and MMP-9. Chemokines are potent signals for inflammatory cell migration into the synovial space. As synoviocytes and endothelial cells of the synovial membrane become activated to express cell adhesion molecules and produce chemokines, neutrophil extravasation into the joint space greatly increases, as was observed in the studies described herein as a steep increase in synovial fluid [neutrophils]. Cells of the synovial membrane also become more permeable to serum proteins (Middleton et al., 2004) resulting in the observed rapid increase in synovial fluid [protein]. MMP-13 (Yammani et al., 2006) and MMP-9 (Soder et al., 2006) are key degradative enzymes in articular cartilage, and the increase in IL-I- induced synovial fluid [GAG] observed in the current study support studies demonstrating substantial upregulation of genes encoding these enzymes in early arthritis (Adarichev et al., 2006; Kydd et al., 2007). Micro-array analysis of pre- arthritic cartilage in PG-stimulated mice revealed that genes encoding for phospholipase C₂, the enzyme catalyzing release of arachidonic acid from nuclear membranes, was not elevated (Adarichev et al., 2006). This may explain, at least in part, why PGE₂ required a longer time course for elevation subsequent to IL-1 stimulation than cell migration and release of GAGs.

Intra-articular challenge with IL-1 did not result in a consistent increase in synovial fluid nitric oxide. IL-1-induced nitric oxide has been frequently reported in cartilage explant models (Pearson et al., 2007; Petrov et at. 2005), cells taken from animal models of acute articular inflammation (Kumar et al., 2006) and clinical cases of articular inflammation (Karatay et al., 2005). This data provides support for evidence that genes encoding inducible nitric oxide synthase are not upregulated in early stage arthritis (Kydd et al , 2007), which delays 11-1 -induced formation of nitric oxide.

SEQ provided protection to IL-1 -stimulated joints as evidenced by: 1) no significant increase in synovial fluid [PGE₂]; 2) increased [GAG] in the synovial fluid prior to IL-1 challenge, then preventing IL-1-jnduced increase in GAG; and 3) limited effusion into the joint space subsequent to IL-1 challenge.

As part of the diet for 2 weeks prior to an intra-articular IL-1 challenge, SEQ prevented significant elevation in IL-1 -induced PGE2. Similar to CON horses, PGE₂ response to IL-1 in SEQ horses peaked at 8h after the second IL-1 injection, but the peak was lower, and did not result in statistically significant changes over time or significant differences between IL-1 and saline injection. This shows that SEQ reduces inflammation and pain associated with elevated PGE₂ in horses with early stage arthritis, and implies that feeding SEQ to horses prior to articular damage may impede progression of the disease to a more advanced stage.

The observed increase in synovial fluid [GAG] of SEQ horses in both saline- and IL-1 -injected joints between pre and inj-1 - ie. before inflammatory challenge - provides evidence for the post-absorptive accumulation of dietary GAGs within the synovial space.

The effectiveness of SEQ in preventing biochemical indicators of early-stage arthritis results from a synergistic effect of its four ingredients.

Published reports have reported significant improvement in arthritic signs in dogs provided with dietary NZGLM (Pollard et al., 2006), and significant protection by glucosamine and chondroitiπ - the major bioactive constituents of SC - of cartilage explants against degradation by IL-1 (Dechant et al., 2005). However, the in vitro PGE2-inhibitory effect of SEQ is greater than that of any of its four constituents alone, per gram of product (Pearson et al. unpublished), suggesting a level of synergism between the ingredients.

Fractionation of Biota Oil

Chromatography Oil from the seeds of Biota Orientalis was fractionated using an Agilent 1200 Preparative HPLC equipped with a diode array detector and an automated fraction collector. The column used was an Agilent Prep C18, 10μm (30 x 250 mm) with the following gradient at a flow rate of 20mlfrninute with a 900μl_ injection of Constituent 4. 0-5 minutes 80% water 20% Acetonitrile. 5-7 minutes Gradient change to 10% water 90% Acetonitrile, 7-25 minutes isocratic 10% water 90% Acetonitrile. Fraction detection was achieved at 254nm.

Mass Spectrometry:

The mass spectrometry detection was performed on an Agilent 6210 MSD Time of Flight mass spectrometry in both positive and negative ion mode. The following electrospray ionization conditions were used, drying gas: nitrogen (7mL min-1, 350"C); nebuliser gas: nitrogen (I5psi); capillary voltage: 4.0 kV; vaporization temperature: 350°C and cone voltage: 60V

Figure 14 shows the chromatographic spectrum of the oil, and various fractions were collected and numbered as shown.

(B) Anti-inflammatory potential of fractions from Biota Oil

To study the anti-inflammatory activities, assays Fr 1 , Fr i, Fr V and Fr Vi were selected and tested at a concentration of ≤ 64μg/ml. The assays carried out to measure the 1) Nitric Oxide (NO) levels, 2) prostaglandin PGE2 levels, 3) prostaglandin PGF2α levels. NHAC cells at passage 3, were stimulated first with-, proinflammatory cytokine IL-1 β at a predetermined concentration 10ng/ml overnight, NHAC Cells were then treated with fractions in the presence of IL-1β 10ng/ml for 24 hours and cell culture supernatant was collected to measure NO, PGE2 and PGF2α levels. Griess Reagent Kit for Nitrite Determination (Molecular Probes, Invitrogen) was used as per kit instructions. For estimation of PGs, High Sensitivity PGE2 & PGF2α EIA kits (Assay Designs Inc.) were used.

As shown in Figure 15, fractions 1 (Fr 1), Fr I₁ and Fr V reduced the NO levels (highly significant) in a dose dependent manner. Fr1 was found to be the most effective among all the four fractions with Fr Vi the least effective, although still showing some effect. The non steroidal anti inflammatory drug lndomethacin used as a positive control significantly reduced the IL-1β induced PGE2 levels. All the four fractions had no effect on these levels at any of the concentrations tested (Figure 16 & 17).

lndomethacin significantly reduced the IU-I (3 induced PGF2α levels. Fr 1 showed no effect at all on the PGF2α levels, while Fr i, Fr V and Fr Vi reduced these levels, in a dose dependent manner (64-32μg/ml) (Figure 18 & 19).

The effectiveness of the biota oil extract fractions has until now not been known. The use of the compounds of F1.1-1.4 either separately or as a mixture with one or more of the other fractions provides for a remarkable improvement in the treatment of conditions, such as osteoarthritis.

Any improvement may be made in part or all of the method steps and systems components. All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended to illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. Any statement herein as to the nature or benefits of the invention or of the preferred embodiments is not intended to be limiting, and the appended claims should not be deemed to be limited by such statements. More generally, no language in the specification should be construed as indicating any non-claimed element as being essential to the practice of the invention. This invention includes all modifications and equivalents of the subject matter recited as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly coπtraindicated by context.

References

Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A,

Mikecz K, Giant TT. (2006) Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity; 39(8):663-73. Aoyama T, Liang B, Okamoto T, Matsusaki T, Nishijo K, lshibe T, Yasura K₁

Nagayama S, Nakayama T, Nakamura T, Toguchida J. (2005) PGE2 signal through EP2 promotes the growth of articular chondrocytes. J Bone Miner Res;

20(3):377-89. Blitek A, Ziecik AJ. (2006) Role of tumour necrosis factor alpha in stimulation of prostaglandins F(2alpha) and E(2) release by cultured porcine endometrial cells. Reprod Domest Anim; 41(6):562-7. Bolam CJ₁ Hurtig MB, Cruz A, McEwen BJ. (2006) Characterization of experimentally induced post-traumatic osteoarthritis in the medial femorotibial joint of horses. Am J Vet Res; 67(3) 433-47. Bui LM₁ Bierer TL. (2003) Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther; 4(4):397-407. Chan PS, Caron JP₁ Rosa GJ, Orth MW. (2006) Glucosamine and chondroitiπ sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage;

13(5):387-94. Chandrasekhar S₁ Esterman MA₁ Hoffman HA. (1987) Microdetermination of proteoglycans and glycosamiπoglycans in the presence of guanidiπe hydrochloride. Anal Bϊochem; 161(1):103-108. Cho SH, Jung YB, Seong SC₁ Park HB₁ Byun KY, Lee DC₁ Song EK₁ Son JH.

(2003) Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Allerg Immunol (Paris); 35(6):212-6.

Dechant JE. Baxter GM, Frisbie DD, Trotter GW. Mcllwraith CW. (2005) Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on, normal and interleukin-1 conditioned equine articular cartilage explant metabolism, Equine Vet J₁ 37, 227-31.

Fehrenbacher A, Steck E, Rickert M, Roth W, Richter W. (2003) Rapid regulation of collagen but not metalloproteinase 1, 3, 13, 14 and tissue inhibitor of metalloproteiπase 1 , 2, 3 expression in response to mechanical loading of cartilage explants in vitro. Arch Biochem Biophys; 410(1):39-47

Fenton Jl. Chlebek-Brown KA, Caron JP, Orth MW. (2002) Effect of glucosamine on interleukin-1 -conditioned articular cartilage. Equine Vet J Suppl; (34):219- 23.

Frisbie DD, Kawcak CE₁ Werpy NM, Park RD. Mcllwraith CW. (2007) Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res; 68(3):290-6.

Gerstenfeld LC₁ Thiede M. Seibert K, Mielke C, Phippard D, Svagr ^β, Cullinane D₁ Einhorn TA. (2003) Differential inhibition of fracture healing by non-selective and cyclooχygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res; 21(4):670-5.

Granja AG, Sabiπa P, Salas ML, Fresno M, Revilla Y. (2006) Regulation of inducible nitric oxide synthase expression by viral A238L-mediated inhibition of ρ65/RelA acetylation and p300 transactivation. J Virol; 80(21): 10487-96. Huakiπsson EC₁ Berry H, Gishen P. (1995) Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol, 22:1941-1946. Hungiπ AP, Keaπ WF. (2001) Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? Am J Med; 110(1 A):8S-11S. limoto S, Watanabe S, Takahashi T, Shimizu A₁ Yamamoto H. (2005) The influence of Celecoxib on matrix synthesis by chondrocytes under mechanical stress in vitro, lnt J MoI Med; 16(6):1083-8. Jacobsen S, Niewold TA, Halling-Thomseπ M₁ Nanni S, Olsen E, Lindegaard C₁

Andersen PH. (2006) Serum amyloid A isoforms in serum and synovial fluid In horses with Ijpopolysaccharide-induced arthritis. Vet Immunol Immunopathol;

110(3-4):325-30 Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K. (2005) Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clin

Rheumatol; 24(5):497-501. Kida Y, Kobayashi M, Suzuki T, Takeshita A₁ Okamatsu Y₁ Hanazawa S, Yasui T₁

Hasegawa K. (2005) lnterleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF- kappaB in human gingival fibroblasts-Cytokine; 29(4): 159-68. Kim SF₁ Huri DA₁ Snyder SH. (2005) Inducible nitric oxide synthase binds. S- nitrosylates, and activates cyclooxygenase-2. Science; 310(5756): 1966-70. Kumar DA, Raju KV₁ Settu K, Kumanan K, Puvanakrishnan R. (2005) Effect of a derivatized tetrapeptide from lactoferrin on nitric oxide mediated matrix metalloproteinase-2 production by synovial fibroblasts in collagen-induced arthritis in rats. Peptides; 27(6): 1434-42. Kusano S, lgarashi N, Sakai S₁ Toida T. [Effect of orally administered chondrosine on uptake of 35S sulfate into rat cartilage] Yakugaku Zasshi; 126(4):297-300. Kydd AS₁ Reno CR₁ Tsao HW₁ Hart DA. (2007) Early inflammatory arthritis in the rabbit: the influence of intraarticular and systemic corticosteroids, on mRNA levels in connective tissues of the knee. J Rheumatol; 34(1): 130-9.

LaPointe MC₁ Isenovic E. (1999) lnterleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension; 33(1 R 2):276-82.

Marciani L₁ Bush D₁ Wright P, Wickham M, Pick B₁ Wright J, Faulks R, Fillery- Travis A. Spiller RC, Gowland PA. (2005) Monitoring of gallbladder and gastric coordination by EPI. J Magn Reson Imaging; 21(1):82-85.

McCarthy G, O'donovan J₁ Jones B, McAllister H, Seed M. Mooney C. (2006) Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 2006 Apr 27;

Mesa Garcia MD₁ Aguilera Garcia CM, Gil Hernandez A. (2006) Importance of lipids in the nutritional treatment of inflammatory diseases. Nutr Hosp; 21 Suppl 2:28-41 , 30-43.

Middleton J₁ Americh L, Gayon R, Julien D, Aguilar.L, Amalric F₁ Girard JP. (2004) Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther; 6(2):60-72.

Neil KM, Caron JP, Orth MW. (2005) The role of glucosamine and chondroitin sulfate in treatment for and prevention of osteoarthritis in animals. J Am Vet Med Assoc; 226(7):1079-88.

Nishimoto S, Takagi M, Wakitani S, Nihira T, Yoshida T. (2005) Effect of chondroitin sulfate and hyaluronic acid on gene expression in a three- dimensional culture of chondrocytes. J Biosci Bioeng; 100(1):123-6. Palmer RM, Hickery MS, Charles IG₁ Moncada S₁ Bayliss MT. (1993) Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun; 193(1) 398-405.

Pearson W, Orth MW₁ Karrow NA, MacLusky N₁ Lindinger Ml (2007) Antiinflammatory and chondroprotective effects of nutraceuticals in a cartilage explant model of inflammation. MoI Nutr Food Res: 2007, 51, 1020-1030.

Petrov R, MacDonald MH₁ Tesch AM, Benton HP. (2005) Inhibition of adenosine kinasa attenuates iπterleukin-1- and lipopolysaccharide-iπduced alterations in articular cartilage metabolism. Osteoarthritis Cartilage; 13(3):250-7.

Pivnenko TN, Sukhoverkhova GIu₁ Epshtein LM, Somova-lsachkova LM, Timchenko NF₁ Besednova NN. (2005) [Experimental morphological study of the therapeutic effect of shark cartilage preparation in a model of infective allergic arthritis] Antibiot Khimioter; 50(5-6,):20-3.

Pollard B₁ Guilford WG₁ Aπkenbauer-Perkins KL₁ Hedderley D. (2006) Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. N Z Vet J; 54(3):114-8.

Rashad S, Revell P, Hemingway A₁ Low F₁ Rainsford K₁ Walker F. (1989) Effect of non-steroidal antiinflammatory drugs on the course of osteoarthritis. Lancet; 2(8662):5i9-22.

Rininger JA, Kickner S, Chigurupati P, McLean A, Fraπck Z. (2000) lmmunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol; 68(4):503-10. Rukwied R, Chizh BA, Lorenz U, Obreja O, Margarit S, Schley M, Schmelz M.

(2007) Potentiation of Nociceptive Responses to Low pH Injections in Humans by Prostaglandin E2. J Pain. 2007 May;8(5):443-51. Schena M₁ Shalon D, Davis RW, Brown PO. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science;

270:467-470. Shen CL₁ Hong KJ₁ Kim SW. (2005) Comparative effects of ginger root (Zingiber officinale Rose.) on the production of inflammatory mediators in normal and osteoarthrotic sow chondrocytes. J Med Food; 8(2):149-53. Shin Jl, Lee YK₁ Kim YM₁ Hwang JT₁ Park OJ. (2007) Possible link between NO concentrations and COX-2 expression in systems treated with soy-isoflavones.

Ann N Y Acad Sci; 1095:564-73. Simmons EJ, Bertone AL, Weisbrode SE. (1999) Instability-induced osteoarthritis in the metacarpophalangeal joint of horses. Am J Vet Res; 60(1):7-13. Soder S₁ Roach HI. Oehler S, Bau B, Haag J, Aigner T. (2006) MMP-9/gelatinase

B is a gene product of human adult articular chondrocytes and increased in. osteoarthritic cartilage. Clin Exp Rheumatol; 24(3):302-4. Steel CM, Hopper BJ, Richardson JL, Alexander GR₁ Robertson ID. (2006) Clinical findings, diagnosis, prevalence and predisposing factors for lameness localised to the middle carpal joint in young Standardbred racehorses. Equine Vet J;

38(2): 152-7. Su XQ, Aπtoπas KN, Li D. (2004) Comparison of n-3 polyunsaturated fatty acid contents of wild and cultured Australian abalone. lnt J Food Sci Nutr;

55(2): 149-54. Toutain PL, Cester CC. (2004) Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint. Am J Vet Res; 65(11): 1533-41. Trumble TN. (2005) The use of nutraceuticals for osteoarthritis in horses. Vet Clin

North Am Equine Pract; 21(3):575-97, v-vi. van den Boom R₁ van de Lest CH, Bull S₁ Brama RA₁ van Weeren PR, Bameveld

A. (2005) Influence of repeated arthroceπtesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints. Equine Vet J; 37(3):250-6. Welch RD₁ Watkins JP, DeBowes RM₁ Leipold HW. (1991) Effects of intra-articular administration of dimethylsulfoxide on chemically induced synovitis in immature horses. Am J Vet Res; 52(6):934-9. Yammani RR₁ Carlson CS, Bresπick AR₁ Loeser RF. (2006) Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. Arthritis Rheum; 54(9):2901-11. Yang IV₁ Chen E, Hasseman JP, Liang W₁ Frank BC, Wang S, Sharov V. Saeed

Al₁ White J, Li J, Lee NH₁ Yeatman TJ₁ Quackenbush J. (2002) Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol; 3(11):0062. Zhao P, Waxman SG, Hains BC. (2007) Extracellular signal-regulated kinase- regulated microglia-neuron signaling by prostaglandin E^ contributes to pain after spinal cord injury. J Neurosci; 27(9):2357-68.

Claims

THE CLAIMS DEFINING THE INVENTION ARE:

1. A method of modulating inflammation in an organism, the method including administering to an organism a composition including a therapeutic amount of an extract from the plant Biota orientølis.

2. The method of claim 1, further characterised in that the composition includes an additional extract such as mussel extract, abalone extract or powder, shark cartilage powder or combinations thereof.

3. The method of claim 1 , further characterised in that the B. orieπtalis extract is produced from a simulated digest mimicking gastrointestinal functioning / processing.

4. The method of claim 3, further characterised in that the method includes inhibiting cox expression in an organism.

5. The method of claim 4, further characterised in that the cox is cox1.

6. The method of claim 4, further characterised in that the cox is cox2.

7. The method of claim 4, further characterised in that the cox expression is inhibited by >70%.

8. The method of claim 2, further characterised in that the composition is a synergistic composition.

9. The method of claim 8, further characterised in that the composition comprises an extract from the plant Biota orientalis at a concentration of 5-30% by weight, shark cartilage at a concentration of 10-30% by weight, abalone extract at a concentration of 10-30% by weight, and mussel extract at a concentration of 40- 60% by weight.

10. A use of a composition including at least one of the compounds selected from the group consisting of (ΘZ.ISS.ISZJ-^.IS-epoxyoctadeca-Θ.H .IS-trienoic acid, cis, cis, cis-9,12,15-octadecatrienoic acid (ALA), cis, cis, cis-6,9,12-octadecatrieπoic acid (GLA)₁ cis, cis-9,12-octadecadienoic acid and 9-Octadecenoic acid for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of anti-inflammatory conditions.

11. The use of claim 10, further characterised in that the medicament includes an additional extract such as pern a mussel extract, abalone extract or powder, shark cartilage powder or combinations thereof.

12. A method of treatment for anti-inflammatory conditions in a mammal, which includes administering to the mammal a therapeutically effective amount of a polyunsaturated fatty acid.

13. The method of claim 12, further characterised in that the orπega-3 fatty acid is selected from the group including: cis,cis,cis-7.10,13-hexadecatrienoic acid; cis.cis.cis-θ.^.iδ-octadecatrienoic acid; cis.cis.cis.cis-Θ.Θ.^.IS.-octadecatetrae- noic acid; cis.cis.cis-H.i^iy-eicosatrienoic acid; cis.cis.cis.cis-β.i 1,14,17- elcosatetraenoic acid; cis^is.cis.cis/cis-δ.δ.H.^.^-eicosapentaenoic acid; cis,cis,cis,cis,cis-7, 10,13,16,19-docosapentaenoic acid; cis,cis,cis,cis,cis,cis- 4,7,10,13, 16, 19-docosahexaenoic acid; cis,cis,cis,cis-9,12,15, 18,21- tetracosapentaenoic acid; and cis, cis, cis, cis, cis, cis-6, 9, 12, 15, 18,21- tetracosahexaenoic acid or mixtures thereof.

14. The method of claim 12, further characterised in that the omega-6 fatty acid is selected from the group including: cis,cis-9,12-octadecadienoic acid; cis.άs.cis- 6,9,12-octadecatrienoic acid; cis,cis-11 ,i4-eicosadienoic acid; cis, cis,cis-8, 11,14- eicosatrienoic acid; cis,cis,cis,cis-5,8,11 ₍i4-eicosatetraenoic acid; cis.cis-13,16- docosadienoic acid; cis,cis,cis,cis-7,10,13,16-docosatetraenoic acid; and cis,cis,cis,cis,cis-4, 7,10,13, 16-docosa-pentaenoic acid or mixtures thereof.

15. The method of claim 12, further characterised in that the omega-9 fatty acid is selected from the group including: cis-9-octadecerioic acid; cis-11-eicosenoic acid; cis,cis,cis-5,8,11-eicosatrienoic acid; cis-13-docosenoic acid; and cis-15- tetracosenoic acid or mixtures thereof.

16. The method of claim 12, further characterised in that the conjugated fatty acid is selected from the group including: ΘZ.HE-octadeca-Θ.H-dienoic acid; 10E.12Z- octadeca-9,11-dienoic acid; 8E,10E,12Z-octadecatrienoic acid; 8E,10E,12E- octadecatrienoic acid; 8E,10Z,12E-octadecatrieπoic acid; 9E,11E,13Z-octadeca- 9,11 ,13-trienoic acid; 9E,11 E,13E-octadeca-9,11,13-trienoic acid; 9Z.11Z.13E- octadeca-9,11,13-trienoic acid; ΘZ.I I E.ISZ-octadeca-Θ.I I .IS-trienoic acid; ΘE.I IZJδE-octadeca-θ.i i .i δ-trienoic acid; ΘE.HZ.ISZ.ISE-octadeca- ' 9, 11 ,13,15-trienoic acid; traπs,trans,trans,trans-octadeca-9,11 ,13,15-trienoic acid; (ΘZ.ISS.ISZJ-^.IS-epoxyoctadeca-Θ.H .IS-trieπoic acid; and 5Z,8Z,10E,12E,14Z-eicosanoic acid or mixtures thereof.

17. The method of any one of claims 12-16, further characterized in that the fatty acid is in a form of a salt.

18. A pharmaceutical preparation for the treatment of anti-inflammatory conditions in a mammal, which includes a therapeutically effective amount of an extract from a Biota orientalis plant.

19. The pharmaceutical preparation of claim 18, further characterized in that the preparation includes an additional extract such as perna mussel extract, abalone extract or powder, shark cartilage powder or combinations thereof.

20. A pharmaceutical preparation for the treatment of anti-inflammatory conditions in a mammal, which includes a therapeutically effective amount of a polyunsaturated fatty acid.

21. The pharmaceutical preparation of claim 20, further characterized in that the polyunsaturated fatty acid is selected from the group consisting of (9Z,13S,15Z)- 12,13-epoxyoctadeca-9, 11,15-trienoic acid, cis,cis,cis-9, 12,15-Octadecatrieπoic acid, cis.cis,cis-6,9,12-octadecatrienoic acid, 9-Octadecenoic acid, Undecanoic Acid, icosa-5,8,11,14-tetraenoic acid or mixtures thereof.